1. Home
  2. SNFCA vs ALLO Comparison

SNFCA vs ALLO Comparison

Compare SNFCA & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNFCA
  • ALLO
  • Stock Information
  • Founded
  • SNFCA 1965
  • ALLO 2017
  • Country
  • SNFCA United States
  • ALLO United States
  • Employees
  • SNFCA N/A
  • ALLO N/A
  • Industry
  • SNFCA Finance: Consumer Services
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SNFCA Finance
  • ALLO Health Care
  • Exchange
  • SNFCA Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • SNFCA 298.3M
  • ALLO 338.9M
  • IPO Year
  • SNFCA N/A
  • ALLO 2018
  • Fundamental
  • Price
  • SNFCA $11.20
  • ALLO $1.37
  • Analyst Decision
  • SNFCA
  • ALLO Strong Buy
  • Analyst Count
  • SNFCA 0
  • ALLO 10
  • Target Price
  • SNFCA N/A
  • ALLO $9.66
  • AVG Volume (30 Days)
  • SNFCA 32.0K
  • ALLO 3.3M
  • Earning Date
  • SNFCA 05-13-2025
  • ALLO 03-13-2025
  • Dividend Yield
  • SNFCA N/A
  • ALLO N/A
  • EPS Growth
  • SNFCA 81.97
  • ALLO N/A
  • EPS
  • SNFCA 1.11
  • ALLO N/A
  • Revenue
  • SNFCA $334,522,668.00
  • ALLO $22,000.00
  • Revenue This Year
  • SNFCA N/A
  • ALLO $110.82
  • Revenue Next Year
  • SNFCA N/A
  • ALLO N/A
  • P/E Ratio
  • SNFCA $10.90
  • ALLO N/A
  • Revenue Growth
  • SNFCA 5.03
  • ALLO N/A
  • 52 Week Low
  • SNFCA $6.19
  • ALLO $1.31
  • 52 Week High
  • SNFCA $13.59
  • ALLO $4.30
  • Technical
  • Relative Strength Index (RSI)
  • SNFCA 28.42
  • ALLO 31.78
  • Support Level
  • SNFCA $12.49
  • ALLO $1.49
  • Resistance Level
  • SNFCA $12.85
  • ALLO $1.69
  • Average True Range (ATR)
  • SNFCA 0.42
  • ALLO 0.15
  • MACD
  • SNFCA -0.10
  • ALLO -0.04
  • Stochastic Oscillator
  • SNFCA 7.22
  • ALLO 8.75

About SNFCA Security National Financial Corporation

Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: